Citation: yoon sh et al.Outcomes of transcatheter mitral valve replacement for degenerated bioprostheses, failed annuloplasty rings, and mitral annular calcification.Eur heart j.2019 feb 1;40(5):441-451.Doi: 10.1093/eurheartj/ehy590.Epub 2018 oct 23.Earliest date of publish used for event date.No unique device identifier (serial/lot) numbers were provided; without this information it could not be determined whether these observations have been previously reported.Without return of the product no definitive conclusion can be made regarding the clinical observations.(b)(4).If information is provided in the future, a supplemental report will be issued.
|
Medtronic received information via literature regarding the clinical outcomes of transcatheter mitral valve replacement for patients with degenerated bioprostheses, failed annuloplasty rings, and severe mitral annular calcification.All data were collected from 40 centers between february 2009 and april 2018.The overall study population included 521 patients (predominantly female; mean age 72 years), 4 of which were implanted valve-in-valve with medtronic melody transcatheter valves (melody valve implanted inside degenerated surgical bioprosthesis).No serial numbers were provided.Among all 322 patients in the valve-in-valve group, 20 deaths occurred within 30 days post implant.Multiple manufacturers were noted in the literature; based on the available information, medtronic product was not directly associated with the deaths.Among all 322 patients in the valve-in-valve group, adverse events included: conversion to surgery, need for second valve implantation, re-intervention (defined as paravalvular leak closure, atrial septal defect closure, alcohol septal ablation, or mitral valve replacement), left ventricle perforation, stroke, valve embolization, left ventricular outflow tract obstruction, mitral stenosis, clinical thrombosis, elevated mean gradients, moderate or higher mitral regurgitation, life-threatening/major or extensive bleeding, major vascular complications, and decreased left ventricular ejection fraction.Based on the available information, medtronic product may have been associated with the adverse events.No additional adverse patient effects or product performance issues were reported.
|